Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted therapy of RET fusion-positive non-small cell lung cancer
Zixiong Shen, Binxu Qiu, Lin Li, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 12

Showing 12 citing articles:

Advancements in NSCLC
Jianan Xu, Lin Tian, Wenlong Qi, et al.
American Journal of Clinical Oncology (2024)
Open Access | Times Cited: 5
A Multi-omic study integrating plasma protein, multiple tissues, and single-cell identifies RNASET2 as a key gene for lung cancer
Jiaxin Shi, Linyou Zhang
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Pancreatic Ductal Adenocarcinoma (PDAC): Clinical Progress in the Last Five Years
Osama Mosalem, Ahmed Abdelhakeem, Nayef Hikmat Abdel-Razeq, et al.
Expert Opinion on Investigational Drugs (2025), pp. 1-12
Closed Access
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial
Dan‐Yun Ruan, Wenwen Huang, Yongsheng Li, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Rearranged during transfection (RET) lung cancer – Update on targeted therapies
William Mullally, C. O’Leary, Kenneth J. O’Byrne
Lung Cancer (2025) Vol. 200, pp. 108083-108083
Closed Access
Efficacy of Selpercatinib in Non-small Cell Lung Cancer With Bilateral Internal Auditory Canal Metastases: A Case Report
Diana Moreira-Sousa, Manuel Morgado, Monica Valente
Cureus (2025)
Open Access
Precision nanomedicine to treat non-small cell lung cancer
Akanksha Dessai, Usha Y. Nayak, Yogendra Nayak
Life Sciences (2024) Vol. 346, pp. 122614-122614
Open Access | Times Cited: 3
Decoding Oncofusions: Unveiling Mechanisms, Clinical Impact, and Prospects for Personalized Cancer Therapies
Kari Salokas, Giovanna Dashi, Markku Varjosalo
Cancers (2023) Vol. 15, Iss. 14, pp. 3678-3678
Open Access | Times Cited: 7
CD133 ligand‐enhanced etoposide‐liposome complex for targeted killing of lung cancer cells
Shiwei Nie, Junzheng Zhou, Xiaodong Zheng, et al.
Biotechnology Progress (2024)
Closed Access
Bioinformatic Approaches for the Detection of Fusion Genes and trans-Splicing Products (A Review)
I. Yu. Musatov, Maxim Sorokin, Anton Buzdin
Russian Journal of Bioorganic Chemistry (2024) Vol. 50, Iss. 3, pp. 657-680
Closed Access
Bioinformatic approaches for detection of fusion genes and <i>trans</i>-splicing products
I. Yu. Musatov, Maxim Sorokin, Anton Buzdin
Биоорганическая химия (2024) Vol. 50, Iss. 3, pp. 231-255
Closed Access
Worldwide analysis of actionable genomic alterations in lung cancer and targeted pharmacogenomic strategies
Gabriela Echeverría‐Garcés, María José Ramos-Medina, Ariana González, et al.
Heliyon (2024) Vol. 10, Iss. 17, pp. e37488-e37488
Open Access
Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib
Giuseppe Lo Russo, Paolo Bironzo, Chiara Bennati, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 194, pp. 104243-104243
Closed Access | Times Cited: 1
Page 1

Scroll to top